Objective To analyze the cost-utility of using extracorporeal oxygenation for patients with
severe acute respiratory distress syndrome in Brazil.Methods A decision tree was constructed using databases from previously published
studies. Costs were taken from the average price paid by the Brazilian Unified
Health System (Sistema Único de Saúde; SUS) over three months in
2011. Using the data of 10,000,000 simulated patients with predetermined outcomes
and costs, an analysis was performed of the ratio between cost increase and years
of life gained, adjusted for quality (cost-utility), with survival rates of 40 and
60% for patients using extracorporeal membrane oxygenation.Results The decision tree resulted in 16 outcomes with different life support techniques.
With survival rates of 40 and 60%, respectively, the increased costs were
R$=-301.00/-14.00, with a cost of R$=-30,913.00/-1,752.00 paid per six-month
quality-adjusted life-year gained and R$=-2,386.00/-90.00 per quality-adjusted
life-year gained until the end of life, when all patients with severe ARDS were
analyzed. Analyzing only patients with severe hypoxemia (i.e., a ratio of partial
oxygen pressure in the blood to the fraction of inspired oxygen <100mmHg), the
increased cost was R$=-5,714.00/272.00, with a cost per six-month quality-adjusted
life-year gained of R$=-9,521.00/293.00 and a cost of R$=-280.00/7.00 per
quality-adjusted life-year gained.Conclusion The cost-utility ratio associated with the use of extracorporeal membrane
oxygenation in Brazil is potentially acceptable according to this hypothetical
study.